Oncoinvent Unveils Encouraging Results from Phase 1 Trial of Radspherin for Ovarian Cancer Treatment Oncoinvent ASA announces promising results from a Phase 1 trial of Radspherin, showcasing its potential in treating ovarian cancer. This marks a key advancement in cancer therapy.

Oncoinvent Unveils Encouraging Results from Phase 1 Trial of Radspherin for Ovarian Cancer Treatment #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent Announces Encouraging Results from Phase 1 Trial of Radspherin® Targeting Ovarian Cancer Oncoinvent ASA reveals promising data from its Phase 1 trial of Radspherin®, demonstrating potential in preventing ovarian cancer progression.

Oncoinvent Announces Encouraging Results from Phase 1 Trial of Radspherin® Targeting Ovarian Cancer #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent ASA's Strong Progress in Ovarian Cancer Research Report Oncoinvent ASA has reported significant advancements in its Phase 2 ovarian cancer trial, showcasing financial discipline and corporate development.

Oncoinvent ASA's Strong Progress in Ovarian Cancer Research Report #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent ASA Reports Progress in Ovarian Cancer Treatment and Financial Discipline Oncoinvent ASA reveals significant advancements in its ovarian cancer clinical trials while maintaining strict financial discipline. This report covers key developments and future plans.

Oncoinvent ASA Reports Progress in Ovarian Cancer Treatment and Financial Discipline #Norway #Oslo #Radspherin #Oncoinvent #OvarianCancer

Oncoinvent Reveals Promising Phase 1/2a Trial Results for Radspherin® in Colorectal Cancer Patients Oncoinvent ASA has announced significant positive results from its Phase 1/2a trial of Radspherin® for patients with colorectal peritoneal metastases, indicating improved survival rates and disease management.

Oncoinvent Reveals Promising Phase 1/2a Trial Results for Radspherin® in Colorectal Cancer Patients #Norway #Oslo #Radspherin #Colorectal_Cancer #Oncoinvent

Oncoinvent's Ovarian Cancer Trial with Radspherin® Shows Promising Results After 18 Months Oncoinvent ASA reveals encouraging 18-month findings from its ongoing ovarian cancer trial with Radspherin®, indicating improved patient outcomes.

Oncoinvent's Ovarian Cancer Trial with Radspherin® Shows Promising Results After 18 Months #Norway #Oslo #Radspherin #Ovarian_Cancer #Oncoinvent

Oncoinvent ASA Announces Successful Completion of Oversubscribed Private Placement to Advance Cancer Treatment Oncoinvent ASA has successfully concluded a private placement, raising NOK 130 million to accelerate the development of their innovative cancer therapy, Radspherin.

Oncoinvent ASA Announces Successful Completion of Oversubscribed Private Placement to Advance Cancer Treatment #Norway #Oslo #Oncoinvent_ASA #Radspherin #Private_Placement